Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 deucravacitinib study in children and adolescents with active juvenile psoriatic arthritis
CTR20253828Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deucravacitinib in juvenile psoriatic arthritis (JPsA), sponsored by Bristol Myers Squibb. Started Feb 2026; status: active.
02
Drugs
deucravacitinib
03
Conditions
juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on CTR20253828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253828.